- Shares of Twist Bioscience Corp TWST fell after the firm issued fiscal second-quarter revenue guidance that fell below the consensus Wall Street estimate.
- For Q1 FY23, Twist posted a 29% increase in sales to $54.2 million, almost in line with the consensus of $54.1 million.
- The company shipped approximately 134,000 genes during the quarter to 2,060 customers, compared to about 1,800 customers during the year-ago quarter.
- For Q1, the company reported an EPS loss of $(0.74), down from $(0.91) a year ago compared to the consensus of $(1.13).
- Guidance: Twist Bioscience expects fiscal Q2 revenues of $56.5 million, below the consensus of $61.9 million, with $24 million in synbio revenues, $25 million in next-generation sequencing revenues, and biopharma revenues of $7.5 million.
- It anticipates full-year fiscal 2023 revenue of $261 million to $269 million, which remains unchanged.
- Price Action: TWST shares are down 16.6% at $25.77 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
